Fig. 1From: Peptide hormone ELABELA promotes rat bone marrow-derived mesenchymal stem cell proliferation and migration by manipulating the cell cycle through the PI3K/AKT pathway under the hypoxia and ischemia microenvironmentELA promotes RAT BM-MSCs proliferation (A) and cell viability (B) and PI3K/AKT is required in this effect under H/I injury at 0 h, 24 h, 48 h and 72 h. The treatment time of ELA (at a concentration of 5 μM) was 12 h prior to H/I injury. *P < 0.05. ELA, ELABELA; RAT BM-MSCs, Rat bone marrow-derived mesenchymal stem cells; H/I, hypoxic-ischemic; LY, LY294002Back to article page